☰

MBTherapeutics

Updating the operating model

Industry
Biotechnology
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of MBTherapeutics's published strategy and is not endorsed by, or produced in cooperation with, MBTherapeutics. Company website

Strategic priorities

MBTherapeutics operates across 4 stated priorities, with the most concrete near-term plan anchored on 100% digital lab for formulation.

Transform the manual, specialist-dependent rheology and formulation R&D unit into a fully digitized laboratory with automated data capture pipelines from analytical equipment to a central data platform, enabling predictive printability modeling.

Scale from lab-prepared formulations to an industrial-grade GMP facility in Montpellier capable of producing pre-filled, standardized cartridges with real-time batch monitoring and Golden Batch quality assurance.

Establish a Plug & Produce standard for the MED-U printer fleet enabling rapid, secure deployment in community pharmacies and hospitals across France and Germany with full regulatory traceability.

Challenges we see

  • Digital Integration

    Simulation-to-Manufacturing Gap

    MB Therapeutics generates formulation data in R&D labs and printing data at clinical sites, but these datasets remain siloed in Excel spreadsheets and disconnected systems, preventing predictive optimization of dosage printing.

    Without a unified data platform correlating rheological lab data with real-world printing performance, the company cannot use AI for dosage optimization and faces delayed time-to-market for new formulations.

  • Operations Manufacturing

    Manual Formulation Bottleneck

    The formulation R&D unit relies on specialist rheology engineers performing manual, retrospective analysis of how pharmaceutical inks behave under thermal stress during hot-melt extrusion and FDM-style 3D printing.

    Manual process monitoring creates a critical bottleneck that delays the launch of three high-demand medicines targeted for 2026, while drug degradation or crystallization goes undetected until post-process analysis.

  • Compliance Regulatory

    Decentralized GMP Compliance

    Traditional GMP standards are designed for controlled factory environments, not community pharmacies. MB Therapeutics must prove to ANSM, FDA, and EMA that its automated decentralized process is as safe and traceable as a factory production line.

    Without automated qualification documentation and a digital audit trail for every customized pill, the company faces regulatory rejection that could stall its entire go-to-market strategy and France 2030 milestone commitments.

  • Digital Integration

    Multi-Site IT/OT Fragmentation

    The company operates across four locations (HQ, Faculty of Pharmacy R&D, CHU Nimes clinical site, GMP facility in development) with no unified IT infrastructure, while the Lynxter CONTROL and HUB software manages printers but lacks enterprise-level data aggregation.

    The traceability gap between printer OT systems and corporate IT systems compromises the 100% audit requirement for pharmaceutical batch release, creating systemic compliance risks as the printer fleet scales.

  • Digital Regulatory

    Cybersecurity for Decentralized Manufacturing

    As MB Therapeutics expands its model to decentralized pilot pharmacies with remote access capabilities, the attack surface for intellectual property theft of proprietary formulations and process sabotage increases significantly.

    A cybersecurity breach at any pharmacy node could compromise the entire decentralized network, destroying trust with regulators and hospital IT departments who view security as a deciding factor in adoption.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Fragmented Data Architecture

    Formulation data from the University of Montpellier R&D lab and printing performance data from CHU Nimes clinical sites are trapped in disconnected Excel spreadsheets and local instrument databases, creating data islands that prevent cross-correlation and predictive analytics.

    Deploy an Industrial Data Platform with automated data pipelines that unify rheological lab data, printing telemetry, and quality metrics into a single source of truth, enabling AI-driven printability prediction and Golden Batch comparison.

  2. Manual Quality Control at Scale

    Current quality control relies on manual, retrospective analysis by specialist rheology engineers. This approach is impossible to scale across a decentralized pharmacy network where each printer produces customized batch-of-one medications for pediatric patients.

    Implement real-time process intelligence with automated sensor feedback and vision-based inspection systems on the MED-U printer fleet, enabling automated batch release documentation and reducing the cost per personalized dose.

  3. Printer Fleet Connectivity and Standards

    The MED-U printer fleet co-developed with Lynxter uses proprietary CONTROL and HUB software designed for individual printer management, lacking the modular plug-and-produce standards needed for rapid deployment and fleet-wide orchestration across pharmacy sites.

    Adopt MTP (Module Type Package) standards for the MED-U printer ecosystem, creating a universal integration framework that allows any pharmacy to deploy and connect a printer to the central monitoring platform with minimal engineering effort.

  4. Cybersecurity Across Distributed Network

    Expanding from a single clinical pilot site to a network of community pharmacies across France and Germany creates significant cybersecurity exposure, with proprietary formulation IP and patient data flowing across multiple unsecured endpoints.

    Implement a Zero Trust security architecture across the entire decentralized network, ensuring identity-based access control, encrypted data transmission, and real-time anomaly detection to protect formulation IP and satisfy hospital IT procurement requirements.

  5. Workforce Scaling and Digital Fluency

    MB Therapeutics plans to triple its workforce by 2025, but finding engineers who understand both additive manufacturing and pharmaceutical quality standards is difficult, creating organizational Black Box Anxiety where new hires cannot navigate complex IT/OT systems.

    Design an integrated onboarding and digital fluency framework with intuitive UX, assisted reality support tools, and standardized digital workflows that reduce dependency on specialist knowledge and accelerate new hire productivity.

What we'd propose

  • Enterprise AI

    Industrial Data Platform for Pharmaceutical 3D Printing

    Design and deploy a unified data platform that aggregates formulation R&D data, printer telemetry, and quality metrics across all MB Therapeutics sites into a single source of truth, enabling predictive printability analytics and automated Golden Batch comparison.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Digital Lab Transformation for Formulation R&D

    Digitize the manual formulation R&D unit at the Faculty of Pharmacy by integrating heterogeneous analytical instruments into an automated data capture platform, replacing paper-based and Excel workflows with a GxP-compliant Laboratory Execution System.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    MTP-Based Modular Printer Fleet Orchestration

    Develop an MTP-compliant integration framework for the MED-U printer fleet that enables standardized plug-and-produce deployment in pharmacies, with centralized fleet management, remote monitoring, and automated process orchestration.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Digital CDMO

    Zero Trust Cybersecurity Framework for Decentralized Pharma

    Design and implement a comprehensive Zero Trust security architecture protecting MB Therapeutics' proprietary formulation IP, patient data, and printer control systems across its distributed network of pharmacies and manufacturing sites.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Digital Twin for GMP Ink Production Facility

    Create a comprehensive digital twin of the new Montpellier GMP pharmaceutical ink production facility, enabling virtual commissioning, process simulation, energy optimization, and predictive maintenance before and during physical operations.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what MBTherapeutics's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data Integration & Analytics 20 → 80
Formulation and printing data trapped in Excel islands across 4 sites; no unified platform for cross-correlation or predictive analytics.
Manufacturing Automation 25 → 85
Manual rheology assessment and quality control processes; GMP facility not yet built; no automated batch release documentation.
IT/OT Convergence 15 → 75
Printer OT systems (Lynxter CONTROL/HUB) disconnected from corporate IT; traceability gap compromises pharmaceutical audit requirements.
Cybersecurity Posture 10 → 70
No documented Zero Trust framework; decentralized pharmacy model expands attack surface for IP theft and process sabotage.
Regulatory Digital Compliance 30 → 85
France 2030 grant creates milestone pressure; manual qualification documentation cannot scale to decentralized GMP model across multiple countries.
Workforce Digital Fluency 20 → 70
Tripling workforce into a startup with undocumented IT/OT systems; high dependency on specialist knowledge creates organizational fragility.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with MBTherapeutics, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].